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Abstract – High-dose propofol is being investigated for
its potential antidepressant effect. Propofol is titrated
to induce burst suppression, a specific EEG pattern.
However, propofol is difficult to dose due to
uncertainty in each patient’s pharmacokinetics (PK)
and pharmacodynamics (PD), and the lack of a
commercially available monitor of propofol
concentration. Clinicians currently infer the proper
drug dose after observing the EEG response to the
given dose. In this report we share our development of
an automated controller to optimally administer
propofol-induced burst suppression. We designed a
deep deterministic policy gradient (DDPG) algorithm,
which includes two deep neural networks and relates
a 2-dimensional action space with a 3-dimensional
state space. Our DDPG prototype did not satisfy our
minimum training criteria. However, we share our
diagnosis of current limitations in training a DDPGbased RL agent to administer propofol to PK-PDsimulated in silico patients. We also discuss potential
solutions to improve RL agent training and
performance.
I.

CLINICAL BACKGROUND

A recent open-label clinical trial at the University
of Utah demonstrated potential efficacy in propofol’s
antidepressant effects [1], which are being further studied
in a randomized controlled trial [2], along with revised
dosing strategies for propofol. In the interventional
group, high-dose propofol is administered to induce a
specific burst suppression ratio (BSR), which is
monitored and measured by the BIS™ Monitor
(Medtronic, Dublin, Ireland), for a specific duration of
time. Burst suppression is an EEG pattern with alternating
periods of bursts and quiescence [3], which is similar to
the EEG patterns observed in electroconvulsive therapy,
and can alternatively be induced by anesthetics like
propofol [4] or isoflurane [5] at higher doses.
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Figure 1. EEG recording of propofol-induced burst suppression during a highdose treatment. The alternating periods of bursts and quiescence are segmented,
then the ratio is determined by dividing the duration of suppressed EEG activity
by the duration of the entire epoch of 60 seconds.

Titrating propofol to execute the treatment
protocol
is
challenging,
because
patients'
pharmacokinetics (PK) and pharmacodynamics (PD) vary
[6, 7], and cannot be determined easily. Without
technological assistance to administer propofol, clinicians
are limited to their intuition and experience. There is
neither a patient-specific nor standardized process to
accurately and reliably control propofol-induced burst
suppression (PIBS). This challenge impacts our clinical
investigation of propofol’s antidepressant effects.
II. TECHNICAL BACKGROUND
Dosing Based on PK-PD Modeling
PK-PD models can offer a way to conceptualize
and estimate a patient’s BSR response to administered
propofol. Parameters from published PK models can be
individualized to a specific patient by relating the
propofol administered to the BSR observed in the patient's
EEG. Effect site concentrations estimated based on the
individualized PK model can then be used to estimate the
patient’s pharmacodynamics. Based on individualized
PK-PD models, the propofol administration can be
adjusted to achieve the desired levels and durations of
burst suppression.
The main limitation of this approach is that
individualizing model parameters would require a careful
experimental design, which is not practical in the clinical
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Figure 2. PK simulation of an administered propofol bolus, illustrating the
accumulation of propofol in the central compartment (red) and in the effect-site
compartment (blue). Drug accumulation in the effect-site lags behind the
accumulation of drug concentration in plasma [7].

Reinforcement learning (RL) is an intuitive goaloriented control technique, which has demonstrated
proficiency in solving challenging robotic tasks [8] and
recently in controlling propofol anesthesia [9]. Without an
explicit control algorithm or an individualized model of
the patient, an RL “agent” may be able to learn optimal
behavior on how to dose propofol and control BSR. The
RL agent learns through experience from a reward
function and observations from the environment.

Figure 4. Block diagram illustrating the general structure of an RL agent’s
interaction with the environment. The Reward is the feedback that enables
training and adjusts the determination of future actions.

Figure 3. An example of a sigmoidal PD Hill Curve, relating effect-site
concentrations to BSR. The concentration-response relationship is nonlinear
and less sensitive to effect-site concentration changes at the BSR extremes. PD
model parameters vary between and within patients.

setting. Neither plasma nor effect-site concentrations can
be verified, because monitors for real-time propofol
concentration monitoring are not available. Without any
previous knowledge of how a particular patient responds
to a drug, clinicians have to rely on population-based
assumptions.
Without prior individualized estimations of a
patient’s PK-PD parameters, we can still apply PK-PD
principles to guide decision making. We can also apply
known, population-based distributions of PK-PD
parameters and use machine learning to develop a
controller that is robust enough to overcome the
challenges of variability, uncertainty, and nonlinearity in
PIBS.
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Though the general structure of reinforcement
learning is relatively simple, we must integrate the
method with a simulated patient-environment; and
properly structure the state space, action space, and
reward function to effectively train the RL agent. We
must also consider human factors, when deploying a RL
agent in the real world.
For example, for commercializing an automated
dosing system, it may be more practical if the clinician is
kept in the control loop, due to regulatory concerns. In this
case, clinicians would manually administer propofol,
while the RL agent provides guidance to their decision
making. The number of recommended dosing
adjustments should be minimized and should not
overburden the clinician.
III. OBJECTIVES
In this report, our objective is to develop and
successfully train a RL agent on simulated patients of the
same age, weight, and sex. Specifically, we seek to train
the RL agent to optimally administer propofol and target
a desired BSR. We hypothesize that our algorithm can
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train a RL agent to reduce the average-absolute BSR error
to <5%.
IV. METHODS
Create Simulated Patient
Published PK-model parameter distributions [7]
and our group’s own estimations of ke0 (mean ± SD of
0.136 ± 0.027 1/min), Hill coefficient (6.57 ± 1.70), and
EC50 (7.40 ± 1.61 mcg/mL) were used to simulate the
pharmacokinetics and -dynamics of 250 female patients
with a height of 187 cm, age of 42 years, and weight of
96 kg.
Prior to any agent action, each simulated patient
received a standard induction: bolus of 3 mg/kg and
infusion of 300 mcg/kg/min.

Define RL State and Action Spaces
The RL state space is defined as:
1) BSR(t) – Target
2) |BSR(t) – Target| – |BSR(t-5 seconds) – Target|
3) Infusion(t)
The BSR Target was defined as 80% BSR.
The first state-variable tracks the proportional
BSR error over each time step. The second state-variable
tracks the change of the absolute BSR error over the last
5 seconds. The third state-variable tracks the represents
infusion rate at time t. Though the infusion rate is not
directly changed by the patient-environment, we believe
that knowledge of the infusion rate can contribute to the
RL agent’s learning.
The RL action space is defined as:
1) Bolus, 0-100 mg
2) Infusion Rate, 0-400 mcg/kg/min
The time step was defined as 60 seconds.
We determined our action space to reflect the
real-world decision making in our clinical investigation:
In order to control BSR, clinicians either delivered a bolus
dose of propofol or they adjusted the infusion rate. In our
Utah NASA Space Grant Consortium

simulation, the RL agent applies both a bolus and infusion
rate at each time step, within the ranges specified above.
Create a RL Agent
We applied a deep deterministic policy gradient
(DDPG) algorithm [10] to create a reinforcement learning
agent, which can handle continuous-multidimensional
state and action spaces to solve complex problems
The DDPG-based RL agent is made up of two
deep neural networks: the actor and the critic. When a
DDPG-based RL agent processes its observations (states)
from the environment (patient), the actor network
determines a set of actions to apply to the environment
(patient), while the critic network estimates the Q-value
from the state-action combination. The Q-value is directly
determined by the reward function and the discounted
future rewards, according to the Bellman equation [11].
The actor is trained to maximize the long-term “reward,”
while the critic is trained to accurately estimate the Qvalues from the combined state-action space.
The reward function is designed to steer the RL
agent towards choosing actions based on specific states
such that its propofol administration choices would
achieve reaching the desired BSR target:
𝜏=𝑡+𝑠𝑡𝑒𝑝

𝑟(𝑠𝑡 , 𝑎𝑡 ) = ∫

| 𝐵𝑆𝑅(𝜏) − 𝑇𝑎𝑟𝑔𝑒𝑡 | 𝑑𝜏

𝜏=𝑡

This reward function is suitable in targeting a
user-specified BSR during the induction and emergence
phases of PIBS. Over the course of training, the function
is designed to reduce the cumulative absolute BSR error.
Training the DDPG Agent
We followed the DDPG training algorithm
described by Lillicrap et al. presented at ICLR 2016 [10],
which specifies how the RL agent is trained, and how the
actor and critic network weights are adjusted. The training
was implemented in MATLAB (MathWorks, Natick,
Massachusetts), using its Reinforcement Learning
Toolbox (version 1.2).
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by the total time (120 time steps x 60 seconds per time
step = 7200 seconds).
Our goal is to observe either a patient with an
average-absolute BSR or an average from treating five
consecutive patients (throughout any of the 250 patients
in training) that satisfies the criterion of average-absolute
BSR error below 5%
V. INITIAL RESULTS
Figure 5. Block diagram illustrating the general structure of the DDPG
algorithm, with the actor and critic networks interacting with the patient model.
The critic network estimates the patient model's Q-value from the state-action
combination. The Loss guides how the critic network adjusts its weights to
optimize the critic's estimation. The actor network adjusts its weights according
to 1) the gradient of critic output with respect to the applied action, and 2) the
gradient of the actor output with respect to the actor weights, which together
make up the overall gradient of the actor’s performance based on Estimated
Q(s,a) [11].

The RL agent was trained on each of the 250
simulated patients consecutively and for 120-steps per
patient, where each step had a duration of 60-seconds.
Ninety seconds after administering the standard induction
dose, the RL agent began administering propofol and
training its deep neural networks.

After training on 250 patients, our DDPG agent
did not meet the training criterion, nor demonstrate
convergence toward the Critic’s estimated discounted
long-term reward. The best absolute-average BSR error
was 7.65% BSR for a single patient, and 14.5% BSR for
a 5-patient average. The DDPG agent also reported an
average-absolute BSR error of over 20% BSR in 103 of
the 250 patients (58.8%).

The Ornstein-Uhlenbeck noise process [12] was
applied to the actor’s action output before being applied
to the patient and the critic network. Noise was used to
promote exploration and avoid convergence toward local
maxima. We selected a noise variance of 0.500 and
variance decay rate of 10-5, which reduces the noise
variance after each time step throughout the entire
training process.
After completing the training for each patient, we
recorded the total reward over the 120-step training
period. We also recorded a 5-patient moving reward
average, which is based on the average of the total
rewards of training five consecutive patients. Based on
the hypothesis, the goal was for the average-absolute BSR
error to be below 5% (criterion).
Because the reward function is a sum of absolute
BSR error, we can calculate this average-absolute BSR
error for each patient by dividing the total reward
accumulated while training the system with that patient
Utah NASA Space Grant Consortium

Figure 6 The 5-patient moving reward average (blue) illustrates the DDPG
agent’s performance as training progresses across patients. The agent’s goal is
to maximize the Q-value (calculated as the negative absolute BSR error and
discounted future negative BSR errors) through each time-step and training for
each patient rewards. Though noise and exploration in the action space can
explain some fluctuations in performance, the DDPG does not demonstrate
long-term improvement. An average-absolute BSR error of 20% is illustrated
(red) to represent the possibility of the DDPG agent becoming “stuck” at the
upper BSR extremes (~100% BSR) throughout the entire training for one
patient. A successfully trained DDPG agent would achieve an average-absolute
BSR error that decreases below the training criterion (yellow) and further
converge toward the discounted long-term reward’s average-absolute BSR
error (green).
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propofol delivery, longer time steps may be required to
realize more significant changes in BSR and in the
reward. The agent could benefit from the addition of
memory and recurrent neural networks, as consecutive
time steps of reduced propofol input may be required to
effectively reduce BSR, as well as moderate the decrease
in BSR over time.

Figure 7 Example of training with patient #121, showing BSR, reward, and
drug administration over time. The drug administration (green) includes a
combination of a bolus and infusion, which affects the BSR (blue) and its
corresponding reward (magenta). Even within a patient, we do not observe a
consistent trend in improving the reward across time steps. The red vertical line
on the BSR plot represents t = 90 seconds after the standard induction dose.

VI. DISCUSSION
For this initial design of DDPG agent, its patientenvironment, and training structure, we reject our
hypothesis, because the DDPG agent did not achieve a
reward that surpasses the minimum training criteria,
across the 250 patients it was trained on.
After observing the BSR signals and the rewards
accumulated for each patient, we suspect that DDPG
agent may be challenged in reducing BSR at the higher
BSR extremes. Figure 7 blue reflects the inability to
moderately decrease BSR (undershoot), while Figure 8
reflects the continual inability to significantly decrease
BSR toward the target BSR of 80%. This can potentially
be attributed to: 1) we cannot apply actions to directly and
rapidly remove propofol from the patient-environment,
and 2) the pharmacodynamic relationship between
propofol concentration and BSR is nonlinear, while our
reward function is linear.
In order to reduce BSR, we must reduce propofol
delivery and rely on the patient to clear propofol through
pharmacokinetics. This clearance is not as rapid as that of
an administered bolus. In order to reinforce reductions in
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Figure 8. Example of a 120-step training with one patient, in which the RL
agent is unable to decrease drug delivery, drug concentration, and BSR in the
simulated training subject. The proposed reward function does not provide
sufficient negative reinforcement to properly adjust the actor.

The reward function, as it was defined, might not
have been properly “shaped” and can lead to a “vanishing
gradient” problem in machine learning, in which the actor
network is unable to adjust its weight, based on the
feedback provided by the reward function. At the higher
concentration and BSR extremes, the slope of the
pharmacodynamic curve diminishes. Given that it is
already difficult to reduce concentration, reducing BSR
also becomes more difficult, while the current rewards
function relies on changes in BSR magnitude. Thus, the
changes in rewards across the action space would also
diminish at the upper BSR extremes. This directly
impacts the gradient of the policy’s performance, which
ultimately impacts how the actor network updates its
weights [10].
VII.

CONCLUSION

We created a PK-PD patient-model and
integrated it into a reinforcement learning algorithm. Our
current RL agent did not satisfy our minimum criterion
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and was unable to converge toward higher rewards and a
lower average-absolute BSR error.
Beyond modifying the reward function to
improve the control of BSR accuracy precision, we must
also train the RL agent to target a specific duration (12-15
minutes) of a specific BSR range (70-90%), as specified
by the high-dose treatment protocol. We can also consider
developing and deploying multiple agents with different
goals, trained by different reward functions through the
PIBS treatment. We must also consider how we integrate
the RL agent with real-world clinical settings. We
currently envision keeping the clinician in the control
loop, and also seek to limit the number of dosing
adjustments (e.g. no more than 5 adjustments) over each
treatment, so that the clinician is not overburdened.
When we have demonstrated successful training
in an RL agent, we plan to train the agents using patientmodels with different sex, height, age, and weight
combinations. Performance of a trained RL agent will be
tested on a patient testing set that has not been seen during
training. We also plan to apply a noise model to the BSR
signal itself. We can evaluate the intra-patient, and interpatient, and inter-treatment performance of a RL-based
control approach for PIBS. If successful, these
improvements in BSR control will directly support our
clinical investigation of PIBS and other potential
applications in anesthesia.
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